[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100584610":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":25,"centralContacts":29,"locations":34,"responsibleParty":50,"collaborators":24,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":24,"eligibilityCriteria":58,"healthyVolunteers":59,"sex":60,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":24,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":73,"overallStatus":37,"whyStopped":24,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Konya City Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Baby of mother diagnosed with GDM","EXPERIMENTAL","For participants who provide consent, residual blood samples from routine complete blood count tests performed at the 6th postnatal hour will be collected. Additionally, infants included in the study will undergo an echocardiographic evaluation by a pediatric cardiologist between postnatal days 3 and 5.",[13],"Diagnostic Test: echocardiographic evaluation and blood phoenixin-14 level",{"label":15,"type":10,"description":16,"interventionNames":17},"healthy infants","For consenting participants, residual blood samples from routine tests (such as complete blood count or jaundice screening) collected at the 6th hour post-birth will be gathered. Additionally, infants included in the study will undergo echocardiographic evaluation by a pediatric cardiologist between the 3rd and 5th days after birth.",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DIAGNOSTIC_TEST","echocardiographic evaluation and blood phoenixin-14 level","For participants who provide consent, blood samples will be collected at 6 hours postpartum. Additionally, infants included in the study will undergo an echocardiographic evaluation by a pediatric cardiologist between postnatal days 3 and 5.",[9,15],null,[26],{"name":27,"affiliation":5,"role":28},"MELEK BUYUKEREN","PRINCIPAL_INVESTIGATOR",[30],{"name":27,"role":31,"phone":32,"phoneExt":24,"email":33},"CONTACT","+903323105000","melekbuyukeren@gmail.com",[35],{"facility":36,"status":37,"city":38,"state":39,"zip":40,"country":41,"countryCode":24,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Melek Buyukeren","RECRUITING","Konya","Karatay","42020","Turkey (Türkiye)",{"type":43,"coordinates":44},"Point",[45,46],32.48464,37.87135,{"lat":46,"lon":45},[49],{"name":27,"role":31,"phone":24,"phoneExt":24,"email":33},{"type":28,"investigatorFullName":36,"investigatorTitle":51,"investigatorAffiliation":5,"oldNameTitle":24,"oldOrganization":24},"Associate Professor","100584610","blood-phoenixin-14-levels-and-echocardiographic-findings-in-infants-of-diabetic-mothers-100584610",false,"NCT06891586","Blood Phoenixin-14 Levels and Echocardiographic Findings in Infants of Diabetic Mothers","Investigation of the Relationship Between Phoenixin-14 Levels and Echocardiographic Findings in Infants of Diabetic Mothers","Inclusion Criteria:\n\n* Infants of diabetic mothers\n* Healthy term infants\n\nExclusion Criteria:\n\n* Infants whose families did not provide consent\n* Infants with a syndromic appearance or congenital heart disease",true,"ALL","1 Day","5 Days",{"count":64,"type":65},84,"ESTIMATED","INTERVENTIONAL",[68],"NA","In this study, the investigators hypothesize that echocardiographic pathologies observed in infants of diabetic mothers are associated with elevated serum phoenixin-14 levels.",[71,72],"Newborn Morbidity","Newborn Complication",[74,75,76],"NEWBORN","phoenixin-14","Infants of Diabetic Mothers","2026-03-26",{"date":79,"type":80},"2026-03-27","ACTUAL",{"date":82,"type":80},"2024-09-01",{"date":84,"type":65},"2026-10-01",{"name":5,"class":6},1]